CD19-CD22 CAR-T cells by Shanghai Biomed-Union Biotechnology for Unspecified B-Cell Lymphomas: Likelihood of Approval
CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.
CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.
What's Your Reaction?
